Ipamorelin: Research Overview, Mechanism of Action & Lab Supply Standards
A summary of published preclinical research on Ipamorelin, a selective growth hormone secretagogue, including proposed mechanisms, GHS-R1a agonism, study findings, and sourcing considerations for Canadian researchers.
What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) and selective agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), also known as the ghrelin receptor. It was developed in the late 1990s and is notable for its high selectivity — stimulating GH release with minimal effect on cortisol, ACTH, prolactin, or other pituitary hormones that are typically elevated by earlier-generation GH secretagogues.
This selectivity profile has made Ipamorelin a useful research tool for studying isolated GH axis stimulation without confounding HPA axis activation. All published research reviewed on this page involves preclinical animal models or in vitro systems. All material supplied by ACCUTIDE is for laboratory research use only (RUO).
Proposed Mechanisms of Action
GHS-R1a (Ghrelin Receptor) Agonism
Ipamorelin binds GHS-R1a with high affinity and selectivity. Receptor activation triggers intracellular phospholipase C and IP3 signaling, elevating intracellular calcium in somatotrophs and stimulating GH secretion. This pathway is distinct from the GHRH receptor pathway used by tesamorelin and CJC-1295.
Selective GH Secretion
Unlike GHRP-6 and other first-generation GH secretagogues, Ipamorelin does not significantly elevate cortisol, ACTH, or prolactin at research doses. This selectivity makes it particularly useful for isolating GH axis effects in neuroendocrine and metabolic studies.
GH Pulse Augmentation
Ipamorelin augments both the amplitude and frequency of GH pulses from pituitary somatotrophs. Research studies have documented a synergistic effect when combined with GHRH analogues (such as CJC-1295), producing GH output greater than either compound alone.
Enteric Nervous System Activity
GHS-R1a receptors are expressed throughout the gastrointestinal tract. Preclinical research has documented Ipamorelin's effects on gastrointestinal motility via ghrelin receptor engagement in the enteric nervous system, independent of its central GH-releasing activity.
Selected Published Research
The following is a selection of peer-reviewed studies available in PubMed. All studies listed involve preclinical animal models or in vitro research. This is not a comprehensive literature review.
Raun K, et al. — European Journal of Endocrinology, 1998
Original characterization study establishing Ipamorelin as a selective GHS-R1a agonist with potent GH-releasing activity and minimal effect on cortisol, ACTH, and prolactin — distinguishing it pharmacologically from earlier GH secretagogues.
Johansen PB, et al. — Growth Hormone & IGF Research, 1999
Examined Ipamorelin's effects on bone mineral density and body composition in rodent models, documenting GH-mediated increases in bone density and lean mass over extended administration periods.
Jimenez-Reina L, et al. — Hormone Research, 2002
Investigated the effects of Ipamorelin on pituitary somatotroph GH secretion patterns in rodent models, characterizing pulse amplitude and frequency changes relative to baseline and to GHRH co-administration.
Voss MH, et al. — Journal of Pharmacology and Experimental Therapeutics, 2008
Examined Ipamorelin's effects on gastrointestinal motility in a rodent postoperative ileus model, documenting normalization of gut motility via ghrelin receptor engagement in the enteric nervous system.
Purity Standards for Research Use
HPLC Purity Analysis
Research-grade Ipamorelin should meet ≥99%+ purity by HPLC. Given the small peptide size, high-resolution HPLC is necessary to distinguish Ipamorelin from truncated synthesis fragments that would otherwise confound receptor binding studies.
Mass Spectrometry (Identity)
MS confirms the correct molecular formula and fragmentation pattern for Ipamorelin (MW 711.87 Da). Identity verification is essential to rule out structurally similar GH secretagogue peptides.
Endotoxin Testing
LAL endotoxin testing is critical for in vivo GH research. Endotoxin activates the HPA axis directly, producing cortisol and GH responses that would confound neuroendocrine studies if undetected.
Certificate of Analysis (COA)
Batch-specific COA documenting HPLC purity, MS identity, and endotoxin results. Required for institutional procurement and essential for correlating experimental results to source material quality.
Sourcing Ipamorelin in Canada
ACCUTIDE Research Supply provides Ipamorelin tested to ≥99%+ HPLC purity with batch-specific COA documentation. All material is lyophilized for stability and ships Canada-wide. For research use only.
Ipamorelin — Canadian Research Supply
HPLC tested · COA every batch · Ships Canada-wide · RUO
Often Researched With
Compounds frequently co-investigated alongside Ipamorelin in preclinical research literature.
Research Use Only Disclaimer: All information on this page is provided for scientific research and educational purposes only. Ipamorelin supplied by ACCUTIDE Research Supply is strictly for laboratory and research use (RUO). It is not intended for human or animal consumption, therapeutic use, or any application outside of controlled research settings. All published studies referenced are preclinical or in vitro research. Findings must not be extrapolated to human use.